Interleukin-10 polymorphisms associated with susceptibility to acute myeloid leukemia

Genetics and Molecular Research : GMR
C FeiX Lai

Abstract

We investigated the association between polymorphisms in interleukin-10 (IL-10) -1082G/A (rs1800896), -819T/C (rs1800871), and -592A/C (rs1800872) and the risk of acute myeloid leukemia (AML) in a Chinese population. A total of 167 primary AML cases and 328 healthy control subjects were recruited at the First People's Hospital of Yunnan Province between March 2009 and January 2012. The polymorphisms rs1800896, rs1800871, and rs1800872 were genotyped by polymerase chain reaction-restriction fragment length polymorphism. Multivariate regression analyses showed that subjects carrying the rs1800871 CC genotype and C allele had a significantly increased risk of AML, with adjusted odds ratios (95% confidence intervals) of 1.72 (1.01-2.97) and 1.38 (1.04-1.81), respectively. Those carrying the rs1800872 G allele had a slightly increased risk of AML, with an adjusted odds ratio (95% confidence interval) of 1.30 (1.01-1.72). Moreover, genotyping results demonstrated that subjects carrying both the rs1800871 C allele and rs1800872 G allele had a moderately increased risk of AML, indicating that the 2 genotypes had a synergistic effect on AML risk (odds ratio = 2.03, 95% confidence interval = 1.24- 3.15). Our results demonstrated that pol...Continue Reading

Citations

May 8, 2016·Journal of Medical Virology·Lawal Dahiru RogoTalat Mokhtari-Azad
Aug 4, 2016·Genetic Testing and Molecular Biomarkers·Ayse Feyda NursalSacide Pehlivan
Nov 13, 2019·Journal of Biochemical and Molecular Toxicology·Suwei ZhangXianheng Wu
Feb 8, 2020·Experimental and Molecular Pathology·Fereshteh Nasiri Ganjineh KetabMaryam Rezazadeh
Apr 4, 2021·Cytokine·Omid Karimdadi SarianiFarhad Zaker
Apr 10, 2021·Medical Oncology·Erin C KaserYujiang Fang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.